• Molecular NameZoledronate
  • SynonymZOL; Zoledronic acid
  • Weight272.09
  • Drugbank_IDDB00399
  • ACS_NO118072-93-8
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-4.95
  • pkaN/A
  • LogD (pH=7, predicted)-8.6
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.57
  • LogSw (predicted, AB/LogsW2.0)1951.08
  • Sw (mg/ml) (predicted, ACD/Labs)9.6
  • No.of HBond Donors5
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds4
  • TPSA172.73
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyZometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding22.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNegligible
  • Half life146 h
  • ExcretionRenal (partial)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A